Neu3 Antibody

What is NEU3 and why are antibodies against it important for research?

NEU3 (sialidase 3) is a membrane-associated sialidase that primarily hydrolyzes gangliosides, with a particular preference for substrates with hydrophobic aglycones . As a member of the mammalian sialidase family, NEU3 plays critical roles in:

• Cell signaling pathways, particularly those involving Ras-mediated signaling

• Cancer progression in multiple malignancies including prostate, colon, and melanoma

• Inflammatory processes and immune cell regulation

• Fibrotic conditions in multiple organs

• Regulation of cell adhesion and migration through modification of cell surface glycoconjugates

Antibodies against NEU3 have become essential tools for investigating these biological processes, as they enable detection, localization, and functional analysis of NEU3 in various experimental systems. Research has demonstrated that NEU3 is upregulated in multiple cancer types, with expression levels correlating with disease progression and prognosis , making NEU3 antibodies valuable diagnostic and research tools.

What are the different types of NEU3 antibodies available for research?

NEU3 antibodies come in several formats with different properties suitable for various research applications:

When selecting an antibody, researchers should consider:

• The species of interest (human vs. mouse NEU3)

• Required applications (WB, IHC, IF, etc.)

• Whether recognition of specific epitopes or conformations is important

• Whether inhibition of enzymatic activity is desired

How can I validate the specificity of an anti-NEU3 antibody?

Validating antibody specificity is crucial for obtaining reliable research results. For NEU3 antibodies, consider these validation approaches:

• Positive and negative controls:

  • Test antibody against recombinant human NEU3 protein

  • Use NEU3-overexpressing cells (e.g., via Ad-NEU3-HA transfection) as positive controls

  • Include empty vector-transfected cells as negative controls

  • Use NEU3 knockout or knockdown cells as negative controls

• Cross-reactivity assessment:

  • Test against related sialidases (e.g., NEU1, NEU2, NEU4) to confirm isoform specificity

  • Verify antibody doesn't recognize other proteins of similar molecular weight

• Molecular weight verification:

  • Confirm detection of the appropriate molecular weight band (~48-52 kDa for NEU3)

  • Note that NEU3 may appear as a double band at approximately 50 kDa in some systems

• Epitope mapping:

  • For detailed validation, epitope mapping can identify the specific regions of NEU3 recognized by the antibody

Example validation result from published research: "Anti-C. perfringens NA antibody recognized a double band at 50 kDa from Ad-NEU3-HA-infected cells that was also recognized by an anti-HA tag antibody but not by preimmune serum... These results indicate that the anti-C. perfringens NA antibody recognized human NEU3" .

What techniques can NEU3 antibodies be effectively used for?

NEU3 antibodies have been successfully employed in multiple research techniques:

For optimal results:

• Titrate antibody concentrations for each application and sample type

• Include appropriate positive and negative controls

• For cell surface detection of NEU3, compare staining of intact versus permeabilized cells

What cross-reactivity exists between antibodies against microbial neuraminidases and human NEU3?

A fascinating aspect of NEU3 research is the cross-reactivity between antibodies against microbial neuraminidases and human NEU3:

• Cross-recognition pattern:

  • Antibodies against Clostridium perfringens neuraminidase (NA) recognize human NEU3 but not NEU1

  • Antisera against some influenza virus neuraminidases (specifically N5 and N6 serotypes) also recognize human NEU3 but not NEU1

• Specificity within microbial NAs:

  • Among C. perfringens NA isoforms, the NanI isoform is primarily responsible for NEU3 cross-recognition

  • NEU3-cross-reactive antibody interacts with NanI but not with NanJ or NanH

• Epitope mapping:

  • Anti-C. perfringens NA antibodies bind to at least five linear epitopes in recombinant human NEU3

  • This cross-reactivity suggests structural homology between microbial NAs and human NEU3

• Implications:

  • "The previously described microbial NA superfamily extends to human sialidases"

  • Therapeutic strategies targeting microbial neuraminidases may affect human NEU3 function

  • Conversely, this cross-reactivity might be leveraged for therapeutic approaches to conditions with excessive NEU3 activity

This cross-reactivity has significant implications for both basic research and therapeutic development: "Strategies designed to therapeutically inhibit microbial NA may need to consider potential compromising effects on human sialidases, particularly those expressed in cells of the immune system" .

How can I detect NEU3 expression in cells and tissues using antibodies?

Detecting NEU3 expression requires careful consideration of methodology based on your experimental goals:

For Western Blot:

• Prepare cell/tissue lysates in appropriate buffer with protease inhibitors

• Separate proteins by SDS-PAGE (typically 10-12% gels)

• Transfer to membrane and block with appropriate blocking buffer

• Incubate with primary anti-NEU3 antibody (1:1000-1:4000 dilution typically recommended)

• Wash and incubate with HRP-conjugated secondary antibody

• Develop using ECL or similar detection method

• Expected molecular weight: 48-52 kDa, sometimes appearing as a double band

For Immunohistochemistry:

• Fix tissue sections (formalin fixation and paraffin embedding common)

• Deparaffinize and rehydrate sections

• Perform antigen retrieval (TE buffer pH 9.0 recommended, citrate buffer pH 6.0 as alternative)

• Block endogenous peroxidase and non-specific binding

• Incubate with primary anti-NEU3 antibody (1:50-1:500 dilution)

• Wash and apply appropriate detection system

• Counterstain, dehydrate, and mount

For Flow Cytometry:

• Prepare cell suspensions (e.g., using trypsin-EDTA for adherent cells)

• For total NEU3, permeabilize cells with 0.1% Triton X-100

• For surface NEU3, use intact cells without permeabilization

• Incubate with anti-NEU3 antibody

• Wash and incubate with fluorophore-conjugated secondary antibody

• Analyze using flow cytometer

Research example: "HMVEC-Ls were detached using 0.25% trypsin-EDTA, in some cases permeabilized with 0.1% Triton X-100, and incubated for 30 min at 4°C with anti-human NEU1 or NEU3 antibodies or a species-matched control antibody (rabbit IgG, Invitrogen)" .

How are NEU3 antibodies used to study NEU3's role in cancer?

NEU3 antibodies have been instrumental in elucidating NEU3's role in various cancers:

Expression analysis in cancer tissues:

• NEU3 is upregulated in multiple cancer types including prostate cancer, where "NEU3 to be upregulated in human prostate cancer compared with non-cancerous tissue, correlating with the Gleason score"

• In melanoma, "high levels of the NEU3 gene were expressed at almost equivalent levels with those in colon cancers"

• Immunohistochemistry with NEU3 antibodies can reveal NEU3 expression patterns in cancer versus normal tissue

Mechanistic studies:

• Signaling pathway analysis: NEU3 antibodies help reveal how NEU3 affects cancer-related signaling pathways:

  • In prostate cancer, NEU3 "regulates tumor progression through AR signaling"

  • NEU3 enhances "phosphorylation of AKT and ERK1/2 in NEU3 overexpressing cells"

• Cell growth and apoptosis studies:

  • Detection of NEU3 after silencing or overexpression reveals its impact on cancer cell phenotypes

  • "NEU3 overexpression resulted in suppression of apoptosis in both PC-3 and LNCaP cells"

  • "NEU3 silencing with siRNA in prostate cancer PC-3 and LNCaP cells resulted in increased expression of differentiation markers and in cell apoptosis"

• In vivo tumor studies:

  • NEU3 antibodies can be used to verify NEU3 knockdown in xenograft models

  • "Immunohistological examination revealed suppressed NEU3 protein expression as well as lowered Ki-67 labeling together with more apoptotic cells in the siRNA-effective cases"

How can NEU3 antibodies be used to study inflammatory processes?

NEU3 has emerged as an important regulator of inflammation, and antibodies against NEU3 provide valuable tools for studying these processes:

Detection of NEU3 in inflammatory cells:

• Anti-NEU3 antibodies can identify NEU3 expression in various immune cells including neutrophils, monocytes, and lymphocytes

• Flow cytometry with NEU3 antibodies can reveal changes in surface versus intracellular NEU3 during inflammation

Studying NEU3's role in neutrophil function:

• NEU3 antibodies help elucidate how NEU3 affects neutrophil morphology and function

• "Human neutrophils treated with NEU3 show a decrease in cortical levels of Sambucus nigra lectin (SNA) staining and an increase in cortical levels of peanut agglutinin (PNA) staining, indicating a NEU3-induced desialylation"

• Anti-NEU3 antibodies can verify NEU3 expression in neutrophils in various activation states

Inflammation and fibrosis models:

• NEU3 antibodies can detect changes in NEU3 expression during inflammation and fibrosis development

• "NEU3 is upregulated in, and is important for the survival of, tumor cells in colon, renal, ovarian, and prostate cancers"

• In pulmonary fibrosis models, NEU3 antibodies have helped demonstrate that "NEU3 is sufficient to induce fibrosis in the lungs, and that this effect is mediated by NEU3's enzymic activity"

Inflammatory signaling pathways:

• NEU3 antibodies can help track how NEU3 influences inflammatory cytokine production

• "In human peripheral blood mononuclear cells, NEU3 upregulates extracellular accumulation of the profibrotic cytokines IL-6 and IL-1β, and IL-6 upregulates NEU3, suggesting that NEU3 may be part of a positive feedback loop potentiating fibrosis"

These applications provide valuable insights into how NEU3 contributes to inflammatory processes and identify potential therapeutic targets.

How do antibodies against NEU3 affect NEU3 enzymatic activity?

Some antibodies against NEU3 can inhibit its enzymatic activity, providing important tools for functional studies:

Inhibitory effects:

• Anti-C. perfringens NA antibodies inhibit human NEU3 sialidase catalytic activity

• "The anti-C. perfringens NA antisera inhibited C. perfringens NA with a 50% effective dose (ED50) of 1:14, and the Ad-Neu3-HA-infected HEK293T cells did so with an ED50 of 1:67"

• This inhibition indicates structural similarities between the catalytic sites of microbial and human neuraminidases

Measurement of inhibitory activity:

• NEU3 enzymatic activity can be measured using fluorogenic substrates like 4-methylumbelliferyl-N-acetylneuraminic acid

• Researchers can pre-incubate NEU3 with antibodies before adding substrate to assess inhibitory effects

• Comparative analysis with known NEU3 inhibitors (e.g., 2-acetylpyridine) helps quantify inhibition potency

Applications in functional studies:

• Inhibitory antibodies provide a tool to distinguish between enzymatic and non-enzymatic functions of NEU3

• In neutrophil studies, comparing the effects of enzymatically inactive NEU3 versus antibody-inhibited NEU3 has revealed that "NEU3 can prime human male and female neutrophils, and that NEU3 is a potential regulator of inflammation"

• In fibrosis models, inhibitory antibodies help determine whether "NEU3 is sufficient to induce fibrosis in the lungs, and that this effect is mediated by NEU3's enzymic activity"

Structural insights:

• Epitope mapping of inhibitory antibodies provides clues about the catalytic domain of NEU3

• The inhibitory effect of anti-microbial neuraminidase antibodies suggests conservation of catalytic sites across species

This inhibitory property makes certain antibodies particularly valuable for mechanistic studies of NEU3 function.

What considerations are important when using NEU3 antibodies in in vivo studies?

When planning in vivo studies with NEU3 antibodies, researchers should consider several factors:

Antibody characteristics for in vivo use:

• Isotype selection (IgG is typically preferred for in vivo applications)

• Purification method (endotoxin levels should be minimal)

• Species cross-reactivity (ensure antibody recognizes the animal model's NEU3)

• Half-life and distribution properties

Validation in animal models:

• Prior to functional studies, verify antibody recognition of NEU3 in the selected animal model

• For mouse studies, confirm whether the antibody recognizes mouse NEU3: "Tested Reactivity: Human, mouse"

Controls and interpretation:

• Include appropriate controls (isotype-matched irrelevant antibodies)

• Consider using NEU3 knockout models as negative controls: "Neu3-null cohorts lacked any measurable Neu3 antigen among uninfected and postinfection tissue samples"

• When studying antibody inhibition, compare results with pharmacological inhibitors: "NEU3 inhibition provides an equally efficacious approach in the mouse and possibly in humans"

Tissue-specific considerations:

• When studying inflammation, note that "NEU3 deficiency significantly reduced the frequency of appearance of disease signs"

• For cancer studies, consider that "NEU3 siRNA introduction caused reduction of cell growth of an androgen-independent PC-3 cells in culture and of transplanted tumors in nude mice"

• In fibrosis models, recognize gender differences: "aspiration of NEU3 has a greater effect on male mice"

Dosing and administration:

• Pilot studies should establish effective dosing regimens

• Consider multiple administration routes based on target tissue

• Monitor for potential immune responses against the antibody itself

Understanding these considerations will help design more effective in vivo studies using NEU3 antibodies.